Health
Eli Lilly Drug Slows Alzheimer’s Disease, Study Finds
- Brain disease slowed 35% over a year and a half, study shows
- Second amyloid-targeting drug to succeed in late-stage trial
This article is for subscribers only.
Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval.
The drug, donanemab, slowed the disease by 35% over a year and a half in a trial of 1,182 patients with early-stage Alzheimer’s, Lilly said Wednesday in a statement. About 24% of subjects on the drug experienced brain swelling and an overlapping 31.4% had bleeding in the brain, side effects that have been seen with similar drugs. The company said it plans to apply for US approval this quarter, and the shares rose as much as 5.1% at the New York market open.